Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Everest Medicines's Debt-to-EBITDA or its related term are showing as below:
FRA:6HN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.48 Med: -0.56 Max: -0.02
Current: -16.48
During the past 8 years, the highest Debt-to-EBITDA Ratio of Everest Medicines was -0.02. The lowest was -16.48. And the median was -0.56.
FRA:6HN's Debt-to-EBITDA is ranked worse than 100% of 306
companies
in the Biotechnology industry
Industry Median: 1.255
vs FRA:6HN: -16.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Everest Medicines Debt-to-EBITDA Related Terms
Everest Medicines Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6HN vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Everest Medicines's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Everest Medicines (FRA:6HN) has a Debt-to-EBITDA of 7.92 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Everest Medicines. According to the industry distribution chart, Everest Medicines ranks #999999 out of 306 companies in the Biotechnology industry.
Is Everest Medicines' Debt-to-EBITDA too high?
Everest Medicines' current Debt-to-EBITDA is 7.92. The Biotechnology industry median Debt-to-EBITDA is 1.26. Everest Medicines' value of 7.92 is 531.1% above this industry median. Based on the distribution chart, Everest Medicines ranks #999999 out of 306 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #999999 out of 306 companies for Debt-to-EBITDA. This places Everest Medicines in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. Everest Medicines' value of 7.92 is 531.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 306 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Medicines's current Debt-to-EBITDA of 7.92 is 531.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Everest Medicines. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current Debt-to-EBITDA is 7.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (FRA:6HN) is currently considered Significantly Undervalued. The stock's GF Value™ is €23.07, compared to a current price of €3.76 — trading 83.7% below its estimated fair value. The current Debt-to-EBITDA is 7.92 and 531.1% above the Biotechnology industry median of 1.26. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Everest Medicines (FRA:6HN), the current Debt-to-EBITDA is 7.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (FRA:6HN) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of €3.76 is trading 83.7% below its estimated GF Value™ of €23.07.
GuruFocus considers Everest Medicines to be Significantly Undervalued.
Key valuation signals for FRA:6HN:
Debt-to-EBITDA: 7.92
GF Value™: €23.07 vs. price of €3.76 (83.7% below fair value)
Industry Position: 531.1% above the Biotechnology median (#999999 of 306)
No single metric tells the full story. See the FRA:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score
Get the complete analysis for FRA:6HN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6HN has been successfully added to your 
